AC Immune SA reports results for the quarter ended June 30 - Earnings Summary

AC Immune SA

05/08/2025 13:41

AC Immune SA ACIU.OQ reported a quarterly adjusted loss of 21 rappen​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -23 rappen.  The mean expectation of three analysts for the quarter was for a loss of 17 rappen per share. Wall Street expected results to range from -20 rappen to -15 rappen per share.

Revenue rose 90.1% to CHF1.31 million from a year ago; analysts expected CHF1.98 million.

AC Immune SA's reported EPS for the quarter was a loss of 21 rappen​.

The company reported a quarterly loss of CHF21.19 million.

AC Immune SA shares had risen by 8.1% this quarter and lost 18.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."

Wall Street's median 12-month price target for AC Immune SA is $9.00, about 75.6% above its last closing price of $2.20

This summary was machine generated from LSEG data August 5 at 12:41 p.m. UTC. ​All figures in Swiss francs unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.17
-0.21
Missed
Mar. 31 2025
-0.21
-0.19
Beat
Dec. 31 2024
-0.19
-0.16
Beat
Sep. 30 2024
-0.20
0.05
Beat